Ayuda
Ir al contenido

Dialnet


Tratamiento de la hemorragia grave con fármacos hemoderivados

  • Autores: A. Villar Camacho, J.C. Juárez Jiménez, José Bruno Montoro Ronsano
  • Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 7, Nº. 2, 2005, págs. 127-133
  • Idioma: español
  • Títulos paralelos:
    • Treatment update of acute hemorrhage with hemoderived drugs
  • Texto completo no disponible (Saber más ...)
  • Resumen
    • The treatment of acute hemorrhage, uncontrollable and with a vital compromise, includes various strategies, both medical as well as surgical. In the pharmacological field, the treatment has been essentially based on the use of diverse hemoderivates, either for the replenishment of their biological activity (fibrinogen, prothrombinic complex's factors) or for their local intrinsic procagulant activity (fibrin adhesive) or for their systemic one (recombinant activated Factor VII). Recently, there have been published in the bibliography controlled studies and specific clinical cases about the potential usefulness of the recombinant activated Factor VII (raFVII) in the control of acute hemorrhage. The results of these studies have created hopeful expectations about the availability of an efficient therapeutic instrument for the acute treatment of a pathologic process that presents a high mortality rate. However, it is not exempt from the logical suspiciousness derived from the usage of high-tech drugs -and, as a result, of high cost-, in critical and hard to objectify situations in terms of evidence. In this work, the available scientific evidence is collected, relative to the use of hemoderivates in acute hemorrhage, with special emphasis on raFVII, with the purpose of facilitating the decision-making about the most adequate therapeutic strategy in an enormously complex clinical situation


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus

Opciones de compartir

Opciones de entorno